The level of unmet need is high in the lupus nephritis market; despite developers’ past attempts to target this indication, no drug has been able to secure approval in the United States or Europe — leaving physicians with a limited number of off-label products to select from when treating their lupus nephritis patients. Nevertheless, drug developers continue to pursue this indication, with three emerging agents currently being tested in Phase III trials.

This white paper summarizes the most notable agents previously in development for lupus nephritis, including a top-line discussion of the possible factors leading to their trial failures; we also analyze the advantages and disadvantages of developing novel therapies for this indication and evaluate the current late-stage lupus nephritis pipeline — providing insights on key emerging biologics and small molecule agents targeting this notoriously difficult-to-treat population.

DRG becomes Clarivate

View Now